Results 161 to 170 of about 63,533 (294)
New approach methodologies in Crohn's disease link molecular disease subtypes to clinical outcomes. [PDF]
Penrose HM +7 more
europepmc +1 more source
Abstract In this report, we describe two cases of diaphragmatic endometriosis with concurrent hepatorenal recess peritoneal involvement managed using robotic‐assisted laparoscopic surgery with the da Vinci Xi platform. In both patients, diaphragmatic implants and hepatorenal recess peritoneal lesions were excised en bloc, followed by resection of ...
Xiaoming Guan +3 more
wiley +1 more source
ABSTRACT Introduction We herein report two patients developing secondary adenocarcinomas arising in colonic segments used for urinary diversion a.m. Lundiana in a population‐based series 16 and 27 years after cystectomy, respectively. Case Presentation Following initial partial resection of the pouch, both patients experienced local recurrence; one ...
Fredrik Liedberg +2 more
wiley +1 more source
Pouch Surgery for Ulcerative Colitis: Navigating Complexity in the Modern Era
ABSTRACT Restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) remains the preferred surgical treatment for patients with ulcerative colitis (UC) who require surgery but wish to avoid a permanent ileostomy. Since its introduction in 1978, IPAA has undergone continuous refinement in response to advances in both medical therapy and ...
Gabriele Bislenghi +4 more
wiley +1 more source
ABSTRACT Background The surgical journey of patients diagnosed with ulcerative colitis (UC) typically begins with an index colectomy, which may be followed by restorative procedures or further operations due to complications. Variation in surgical strategies exists, impacting patient outcomes.
Orestis Argyriou +5 more
wiley +1 more source
Combination of Upadacitinib and Risankizumab in Refractory Crohn's Disease
ABSTRACT Background and Aim Dual targeted therapies (DTT) are a promising off‐label approach for the treatment of refractory Crohn's disease (CD). Upadacitinib and risankizumab are approved for the treatment of moderate to severe CD. Our aim was to evaluate the effectiveness and safety of a combination of upadacitinib and risankizumab for refractory CD.
Clara Ramos‐Belinchon +5 more
wiley +1 more source
A Distinct Tryptophan Metabolic Phenotype Marks Severe Fatigue in Quiescent Crohn's Disease
ABSTRACT Background Fatigue is a common and debilitating symptom in inflammatory bowel disease (IBD), but its underlying mechanisms remain unclear. Altered tryptophan metabolism may contribute to fatigue. Tryptophan is metabolized through the kynurenine, serotonin, and indole pathway, involving host and microbial processes. We aimed to explore the link
Paula I. Metselaar +12 more
wiley +1 more source
ABSTRACT Background and Aims Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) represent a unique clinical syndrome affecting up to 80% of PSC patients, characterised by distinct epidemiological patterns, pathophysiological mechanisms and clinical outcomes that differ substantially from either condition occurring independently ...
Luisa Bertin +7 more
wiley +1 more source
Pouch cancer in familial adenomatous polyposis. Incidence, risk factors and literature review: a propos of three rare cases. [PDF]
Campos FG +6 more
europepmc +1 more source

